SNY stock news · Sanofi
Get alerts for SNY
Follow Sanofi (SNY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SNYRegeneron had a great third quarter, earning $20.07 per share and boosting its stock by 11.46%.
NeutralThe story reports more collaboration revenue for Regeneron, but gives no change in Sanofi’s own sales or profits. It does not change Sanofi’s outlook here.
Regeneron had a great third quarter, earning $20.07 per share and boosting its stock by 11.46%.
NeutralThe article reports higher revenue for Regeneron from its Sanofi collaboration, but says nothing about Sanofi’s own sales or profit. It therefore does not change Sanofi’s outlook.
Sanofi's sales hit $16.623 billion last quarter, and Dupixent sales grew a lot, but the CEO is planning for its future without it.
Good for SNYSanofi beat sales and adjusted profit-per-share forecasts and raised its 2026 sales forecast. Dupixent's growth outweighs falling vaccine sales and concern about future competition.
Sanofi's sales jumped 14.3% last quarter, and the company raised its expectations for the whole year.
Good for SNYSanofi reported rising sales and raised its 2026 forecasts for sales and profit per share. This points to a stronger business outlook, despite its search for medicines ahead of patent expirations.
Sanofi is extending its 20-year partnership with Regeneron and promises to invest up to $8 billion.
NeutralSanofi pays $1 billion upfront and half of new program costs, then shares future profits equally. It gains four drug candidates, while Dupixent's current profit split stays unchanged, so the deal does not clearly shift its outlook.
Sanofi withdraws Dupixent application in Europe following concerns from the European Medicines Agency.
NeutralSanofi's decision to withdraw its regulatory application for Dupixent in Europe due to concerns raised by the European Medicines Agency marks a significant setback for the drug, which was initially approved in the U.S. This regulatory hurdle could adversely affect both Sanofi's and Regeneron's market positions and future revenue expectations from Dupixent.
Bill Cassidy claims that Trump's decision to reduce childhood vaccine recommendations to 11 is misguided.
Bad for SNYSanofi's Vaxelis vaccine may see reduced demand due to the new executive order's recommendations.